SNAI1 and plasma cell myeloma: This is consistent with previous studies highlighting PSMD14 inhibitors in other malignancies: they have been shown to enhance bortezomib sensitivity and exert synergistic anti-myeloma effects (40), while thiolutin has been identified as a potential treatment in esophageal squamous cell carcinoma by promoting Snail degradation (41).